Publications

ASCOT Publications - Updated June 2016

 

 

* Meta-analyses

 

­2016

Khamis RY, Hughes AD, Caga-Anan M, Chang C-L, Boyle J, Kojima C, Welsh P, Sattar N, Johns M,  Sever P, Mayet J, Haskard DO. High serum immunoglobulin G and M levels predict freedom from adverse cardiovascular events in hypertension: A nested case-control substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. EBio Medicine 2016;9:372-380.  


Kaasenbrood L, Poulter N, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt M, Pressel SL, Davis BR, van der Graaf Y, Visseren FL.  on behalf of CARDS, ALLHAT and ASCOT investigators.  Development and validation of a model to predict absolute vascular risk reduction by moderate-intensity statin therapy in individual patients with type 2 diabetes mellitus: the ASCOT, ALLHAT and CARDS study. Circ Cardiovasc Qual Outcomes 2016;9(3):213-221.


2015

Joshi PK, Esko T, Mattsson H, Eklund N, Gandin I, Nutile T el al. Directional dominance on stature and cognition in diverse human populations. Nature 2015;523:459-462.*

 

Brown CE, McCarthy NS, Hughes AD, Sever PS, Stalmach A, Mullen W, Dominiczak AF, Sattar N, Mischak H, Thom S, Mayet J, Stanton AV, Delles C. Urinary proteomic biomarkers to predict cardiovascular events. Proteomics Clin. Appl 2015;9:610-617.

 

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRossa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomised trials.  Eur Heart J 2015;36:1536-1546.*  

 

Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015;385:2264-2271.*

 

Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Felix R, Powell C, Vedantam S, Buchkovich ML, Yang J et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518;197-206.*

 

Pers TH, Karjalainen JM, Chan Y, Westra HJ, Wood AR, Yang J, Lui JC, Vedantam S, Gustafsson S, Esko T, Frayling T, Speliotes EK; Genetic Investigation of ANthropometric Traits (GIANT) Consortium, Boehnke M, Raychaudhuri S, Fehrmann RS, Hirschhorn JN, Franke L. Biological interpretation of genome-wide association studies using predicted gene functions. Nat Commun 2015;6:5890.*

 

Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015385(9976):1397-13405.*

  

2014

Davies JE, Lacy P, Tillin T, Collier D, Cruickshank JK, Francis DP, Malaweera A, Mayet J, Stanton A, Williams B, Parker KH, McG Thom SA, Hughes AD. Excess pressure integral predicts cardiovascular events independent of other risk factors in the conduit artery functional evaluation substudy of Anglo-Scandinavian Cardiac Outcomes Trial. Hypertens 2014;64(1):60-68.  

 

Postmus I, Trompet S, Deshmukh HA, Barnes MR Li X, Warren HR et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Communications 2014;5:5068.*

 

Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, Chu AY, Estrada K, Luan J, Kutalik Z, Amin N, Buchkovich ML, Croteau-Chonka DC, Day FR, Duan Y, Fall T, Fehrmann R, Ferreira T, et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet 2014 46:1173-1186.*

 

Jacobs L, Thijs L, Jin Y, Zannad F, Mebazaa A, Rouet P, Pinet F, Bauters C, Pieske B, Tomaschitz A, Mamas M, Diez J, McDonald K, Cleland JGF, Brunner-La Rocca HP, Heymans S, Latini R, Masson S, Sever P, Delles C, Pocock S, Collier T, Kuznetsova T, Staessen J,. On behalf of the Heart ‘omics’ in AGEing (HOMAGE) investigators.   Heart ‘omics’ in AGEing (HOMAGE): design, research objectives and characteristics of the common database.  J Biomed Res. 2014;28(5):349-359.

 

Sever P. The BMJ statins papers misrepresent the facts. Letter. BMJ 2014;348:g4030 doi: 10.1136/bmj.g4030 (Published 18 June 2014).

 

Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci.  Am J Hum Genet. 2014;94:349-360.*

 

Welsh P, Poulter NR, Chang CL, Sever PS, and Sattar N; on behalf of the ASCOT Investigators. The value of N-Terminal Pro-B-Type natriuretic peptide in determining antihypertensive benefit. Hypertens 2014;63:507-513.

 

Barron AJ, Hughes AD, Sharp A, Baksi AJ, Surendran P, Jabbour RJ, Stanton A, Poulter N, Fitzgerald D, Sever P, O’Brien E, Thomas S, Mayet J: ASCOT Investigators.   Long-term antihypertensive treatment fails to improve E/e’ despite regression of left ventricular mass: an Anglo-Scandinavian Cardiac Outcomes Trial Substudy. Hypertension 2014;63:252-258.

 

2013

Prieto-Merino D, Dobson J, Gupta AK, Chang CL, Sever PS, Dahlof B, Wedel H, Pocock S and Poulter NR, on behalf of the ASCOT-BPLA Investigators. ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. J Hum Hypertens 2013;27:492-496.

 

Yadav S, Cotlarciuc I, Munroe PB, Khan MS, Nalls MA, Beven S, Cheng Y-C, Malik R, McCarthy NS et al. Genome-wide analysis of blood pressure variability and ischemic stroke. Stroke 2013;44:2703-2709.*

 

Sever PS, Poulter NR, Chang CL, Thom S, Hughes AD, Welsh P, Sattar N.   Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: A cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. JACC 2013;62:717-729.

 

den Hoed M, Eijgelsheim M, Esko T, Brundel BJ, Peal DS, Evans DM, Nolte IM, Segrè AV, Holm H, et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet 2013;45:621-631.*

 

2012

Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB et al. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet. 2012; 90(3):410-425.*

Erratum in Am J Hum Genet. 2012 Apr 6;90(4):753. Sever, Peter [added]; Poulter, Neil [added] Bhatt, Deepak [corrected to Bhatt, Deepak L]; Asselbergs, Folkert [corrected to Asselbergs, Folkert W].

 

Surendran P, Vangjeli C, McCarthy N, Thom S, Sever PS, O’Brien E, Poulter NR, Mayet J, Hughes A, Caulfied M et al. Genome-wide association analysis identifies the MTHFR-CLCN6-NPPB gene cluster as an important influence on BNP levels - implications for the use of BNP levels in the diagnosis and therapeutic monitoring of heart failure- an ASCOT sub study.  J Hum Hypertens 2012;26:620-620.

 

Asselbergs FW, Guo Y, van Iperen EP, Sivapalaratnam S, Tragante V, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 2012;91:823-838.*

 

Sever PS, Chang CL, Prescott MF, Gupta AK, Poulter NR, Whitehouse A, Scanlon M. Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Euro Heart J 2012: 33;2970-2979.

 

Sever PS. The Anglo-Scandinavian Cardiac Outcomes Trial: Implications and Further Outcomes. Hypertension 2012;60:248-259.

 

Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN, Fuller JH, Livingstone S, Charlton-Menys V, Neil A, Poulter N, Sever P, Shields DC, Stanton AV, Chatterjee A, Hyde C, Calle RA, Demicco DA, Trompet S, Postmus I, Ford I, Jukema JW, Caulfield M, Hitman GA; CARDS, ASCOT, and PROSPER Investigators. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res. 2012;53(5):1000-1011.*

 

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PloSone 2012;7(1):e29849.*

 

Sever PS, Poulter NP, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P and Sattar N.; on behalf of the ASCOT Investigators. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J  2012;33:486-494. (Epub doi:10.1093).

 

2011

Lanktree MB, Guo Y, Murtaza M, Glessner JT, Bailey SD, Onland-Moret NC, Lettre G et al. Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am I Hum Genet. 2011;88:6-18.*

 

Johnson T, Gaunt TR, Newhouse SJ, PadmanabhanS, Tomaszewski M et al . Blood pressure loci identified with a gene-centric array. Am J Hum Genetics 2011;89:1-13.*

 

Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlof B, Poulter NR; for the ASCOT investigators.  Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): a risk score to identify those at high risk. J Hypertens 2011;29:2004-2013.

 

Gupta AK, Prieto-Merino D, Dahlof B, Sever PS, Poulter NR, on behalf of the ASCOT Investigators. Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14,120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. Diabetic Med 2011;28(8):941-947.

 

Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid lowering arm in the UK. Eur Heart J 2011;32:2525-2532.

 

Chapman N, Chang CL, Caulfield M, Dahlof B, Feder G, Sever PS, Poulter NR. Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).   Ethn Dis 2011;21(2);150-157.

 

Sever PS, Poulter NP, Chang CL, Hingorani A, Thomas SA, Hughes AH, Welsh P, Sattar N, on behalf of the ASCOT Investigators. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: Observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J   2011 doi:10.1093/eurheartj/ehr262

 

Collier DJ, Poulter NR, Dahlof B, Sever PS, Wedel H, Buch J, Caulfield MJ, for the ASCOT Investigators. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA).   J Hypertens 2011;29:583-591.

 

Collier DJ, Poulter NR, Dahlof B, Sever PS, Wedel H, Buch J, Caulfield MJ, for the ASCOT Investigators. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens 2011;29:592-599.

 

Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension. Uusimaa P, Peuhkurinen S, Ylitalo A, Vuolteenaho O, Risteli J, Peuhkurinen K; Anglo Scandinavian Cardiac Outcomes Trial Investigators. Acta Cardiol. 2011;66:21-7.

 

2010

High adherence and concordance within a clinical trial of antihypertensives.  Horne R, Clatworthy J, Hankins M; ASCOT Investigators. Chronic IIIn 2010;6:243-251.

 

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1680.*

 

Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D et al for the Global BPgen Consortium. Genome-wide association study of blood pressure extremes identifies variant near UMOPD associated with hypertension. PLoS Genet 2010;6(10): e1001177.*

 

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.*

 

Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, Caulfield M, Collier D, Cruickshank K, Sever PS and Feder G on behalf of ASCOT investigators.   Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT. Am J Hypertens 2010;23:1023-1030.

 

Lindgren P, Eriksson J, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, Wedel H, Jonsson B, on behalf of the ASCOT Investigators. The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian Cardiac Outcomes Trial. Int J Clin Pract 2010;64:1228-1234.

 

Manisty C, Mayet J, Tapp RJ, Parker KH, Sever P, Poulter NR, Thom SAM, Hughes AH, on behalf of the ASCOT Investigators.   Wave reflection predicts cardiovascular events in hypertension individuals independent of blood pressure and other cardiovascular risk factors.   JACC 2010;56:24-30.

 

Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I and Sattar, N.   Statins and all-cause mortality in high-risk primary prevention: a meta-anlaysis of 11 randomised controlled trials involving 65,229 participants.   Arch Intern Med  2010;170:1024-1031.*

 

Gupta AK, Dahlof B, Sever PS, Poulter NR; on behalf of the ASCOT investigators.   Metabolic syndrome, independent of its components, is a risk factor for stroke and death, but not for coronary heart disease among hypertensive patients in the ASCOT-BPLA.   Diab Care. 2010;33:1647-1651.

 

Tapp RJ, Sharp A, Stanton AV, O'Brien E, Chaturvedi N, Poulter NR, Sever PS, Thom SA, Hughes AD, Mayet J; ASCOT Investigators.   Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy.  J Am Coll Cardiol. 2010;55(17):1875-1881.

 

Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Poulter NR, Sever PS on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of β-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-480.

 

Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet  2010;375:895-905.

 

Clunn GF, Sever PS, Hughes AD. Calcium channel regulation in vascular smooth muscle cells: Synergistic effects of statins and calcium channel blockers. Int J Cardiol  2010;139:2-6.

 

2009

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, et al, for the ASCOT Investigators. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. Pharmacoeconomics 2009;27(3):221-230.

 

Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, et al. for the ASCOT investigators; NORDIL investigators; BRIGHT Consortium.   Gene-centric association signals for lipids and apolipoproteins identified via the human CVD BeadChip.   Am J Hum Genet 2009;85(5):628-642.*

 

Sharp, ASP, Tapp, R, Thom S, Francis D, Hughes AD, Stanton AV, Zambanini A, O’Brien, E, Chaturvedi N, Lyons S, Byrd S, Poulter NR, Sever PS and Mayet J, on behalf of the ASCOT Investigators. Tissue Doppler E/E’ ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Euro H Journal 2009;31(6):747-752.

 

Poulter NR, Dobson JE, Sever PS, Dhalof B, Wedel H, Campbell NRC, on behalf of the ASCOT Investigators. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009;54(13):1154-1161. 


Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis.  Diab Care 2009;32:1924-1929.*


Stettler C, Witt N, Tapp RJ, Thom S, Allemann S, Tillin T, Stanton A, O’Brien E, Poulter NR, Gallimore JR, Hughes AD, Chaturvedi N.  Serum amyloid A, C-reactive protein, and retinal mircovascular  changes in hypertensive diabetic and nondiabetic individuals.  Diab Care 2009;32:1098-1100.


Manisty C, Mayet J, Tapp RJ, Sever PS, Poulter N, Thom SA, Hughes AD for the ASCOT Investigators. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2009;54(5):1009-1013.


Manisty CH, Zambanini A, Parker KH, Davies JE, Francis DP, Mayet J, McG Thom SA, Hughes AD; Anglo-Scandinavian Cardiac Outcomes Trial Investigators.  Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy.  Hypertension 2009;54:724-730.


Patel JV, Lim HS, Dubb K, Hughes EA, Lip GY. Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension. Ann Med 2009;41(4):291-300.


Williams B, Lacy PS; CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators.   Impact of hear rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate.  J Am Coll Cardiol 2009;54:705-713.


Thom S, Stettler C, Stanton A, Witt N, Tapp R, Chaturvedi N, Allemann S, Mayet J, Sever P, Poulter N, O’Brien E, & Hughes, A. Differential effects of antihypertensive treatment on the retinal microcirculation. An Anglo-Scandinavian Cardiac Outcomes Trial Substudy. Hypertension 2009;54:405-408.


Sever PS, Poulter NP, Mastorantonakis S, Chang CL, Dahlof B, Wedel H. Coronary heart disease benefits from blood pressure and lipid-lowering. Int J Cardiol  2009;135:218-222.

 

Dolan E, Stanton AV, Thom S, Caulfield M, Atkins N, McInnes G, Collier D, Dicker P, O'Brien E; ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.   J Hypertens 2009;27:876-885.

 

Sever PS, Poulter NR, Dahlof B, Wedel H on behalf of the ASCOT Investigators. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.  J Hypertens 2009;27(5):947-954.

 

Sever PS, Poulter NR, Mastorantonakis S, Chang CL, Dahlof B, Wedel H, for the ASCOT Investigators. Coronary heart disease benefits from blood pressure and lipid-lowering. Int J Cardiol. 2009;135:218-222.


2008

Ostergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E; for the ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.   J Hypertens 2008;26(11):2103-11.

 

Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR; on behalf of the ASCOT Investigators.   Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118:42-48.

 

Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR; on behalf of the ASCOT investigators.   Determinants of new-onset diabetes among 19,257 hypertensive patients randomised in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diab Care  2008;31(5):982-988.

 

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B. Economic Evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen. Heart  2008; 94:1-5.

 

Sever P, Dahlöf B, Poulter N, Wedel H. Beevers G, Caulfield M, Collins R, Kjeldsen S, Kristinsson A, Mehlsen J, Nieminem M, O’Brien E, Ostergren, ASCOT Steering Committee Members.   The Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm: Extended Observations 2 Years After Trial Closure. Euro Heart J  2008;29:499-508.

 

Sharp A, Tapp R, Francis DP, McG Thom SA, Hughes AD, Stanton AV, Zambanini A, Chaturvedi N, Byrd S, Poulter NR, Sever PS, Mayet J. Ethnicity and left ventricular diastolic function in hypertension: an ASCOT (Anglo Scandinavian cardiac Outcomes Trial) substudy. J Am Coll Cardiol  2008;52:1015-1021.

 

 

2007

Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR. Effect of Spironolactone on Blood Pressure in Subjects with Resistant Hypertension. Hypertension 2007;49(4):839-845.

 

Spencer CG, Felmeden DC, Blann AD, Lip GY. Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Am J Hypertens  2007;20(6):699-704.

 

Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med 2007;261:384-391.


Bloch MJ, Basile J.  Effects of a calcium channel blocker and a statin-based treatment regimen in the Anglo-Scandinavian Cardiac Outcomes Trial.  J Clin Hypertens  2007;9:145-147.  


Spencer CG, Felmeden DC, Blann AD, Lip GY. Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med 2007;261(1):82-90.

 

Lindgren P, Kahan T, Poulter N, Buxton M, Svarvar P, Dahlöf B, Jonsson B; ASCOT investigators. Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. Eur J Health 2007;8(1):25-30.

 

2006

Sever P, Dahlöf B, Poulter N, Wedel H. Beevers G, Caulfield M, Collins R, Kjeldsen S, Kristinsson A, Mehlsen J, Nieminem M, O’Brien E, Ostergren, ASCOT Steering Committee Members.

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J  2006;27:2982-2988.

 

Coleman JJ, Kendall MJ. The Anglo-Scandinavian Cardiac Outcomes Trial - blood pressure lowering arm. J Clin Pharm Ther 2006;31:299-307.


Meurin P.  The ASCOT trial: clarify the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension.  Am J Cardiovasc Drugs 2006;6:327-334.

 

Julkunen J, Ahlström R. Hostility, anger, and sense of coherence as predictors of health-related quality of life. Results of an ASCOT substudy. J Psychosom Res 2006;61:33-39.

 

Aksnes TA, Kjeldsen SE, Mancia G. The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines? Am J Cardiovasc Drugs 2006;6:139-147.*

 

Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225.

 

2005

Anglo-Scandinavian Cardiac Outcomes Trial: History, results and implications for clinical practice.   Eds Poulter NR, Sever P 2005. Sherborne Gibbs Ltd Publications.

 

Sever P. ASCOT - a four horse race. JRAAS 2005; 6(2):51-54.

 

Krzesinski JM.  First evidence of greater cardiovascular protective effects of newer as compared to old antihypertensive drugs treatments: the ASCOT-BPLA results]. [Article in French]. Rev Med Liege  2005;60(10):820-826.

 

Sever PS. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)? Am J Med  2005; 118 Suppl 12A: 3S-9S.

 

Kaplan NM. Treatment of hypertension: remaining issues after the Anglo-Scandinavian Cardiac Outcomes Trial. Hypertens 2006;47(1):10-13.


Tseng KH. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Sever et al. Diab Care 2005;28:2595.

 

Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 2005;258:336-343.

 

Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; for the ASCOT Investigators.   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.  Lancet 2005; 366: 895-906.

 

Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S; for the ASCOT Investigators    Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913

 

Sever P, Poulter N, Dahlöf B, Wedel H for the ASCOT Investigators.   Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol  2005;96[Suppl]:39F-44F.  

 

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.   Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care  2005;28(5):1151-1157.

 

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jonsson B; on behalf of the ASCOT investigators.   Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil 2005;12:29-36.

 

Sever P. Treating hypertensive patients: the message from ASCOT-BPLA. Practical Cardiovasc Risk Management  2005; 3 (4): 1-3.

 

2004

Sever PS, Dahlöf   B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.   Drugs  2004;64 Suppl 2:43-60.

 

de Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B, Romero R, De Leeuw PW, Hitzenberger G, Battegay E, Duprez D, Sever P, Safar ME.   Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens  2004;17:660-667.

 

Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho O, Ruskoaho H, Risteli J, Linnaluoto M, Peuhkurinen K; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol. 2004;97:251-256.

 

Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).  Am J Hypertens 2004;17:764-769.

 

Nambi V, Ballantyne CM. ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. Curr Atheroscler Rep 2004;6:353-358.

Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY.  Platelet indexes in relation to target organ damage in high-risk hypertension patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).  J Am Coll Cardiol 2004;44:415-422.

 

Armitage J, Bowman L. Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol 2004;15(4):439-446.*

Szucs TD, Klose G, Düsing R. Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].   [Article in German]. Dtsch Med Wochenschr. 2004;129:1420-1424.

 

Spencer CG, Martin SC, Felmeden DC, Blann AD, Beevers GD, Lip GY. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Int J Cardiol 2004;94:293-300.

 

Farmer JA. Anglo-Scandinavian Cardiac Outcomes Trial--Lipid lowering arm. Curr Atherscler Rep 2004;6:87-88.

Spencer CG, Gurney D, Felmeden DC, Blann AD, Beevers DG, Lip GY.   Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).  J Intern Med 2004;255:59-67.


Hennekens CH.  he ALLHAT-LLT and ASCOT-LLA trials: are the discrepancies more apparent than real? Curr Atherscler Rep 2004;6:9-11.

 

2003

Scheen AJ. Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based medicine. [Article in French] Rev Med Liege 2003;58:585-590.

 

Brown WV, Moussa M. Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm. Curr Opin Lipidol  2003;14:593-597.


Felmeden DC,  Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG, Lip GY.  Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT].  Am J Cardiol 2003;92:400-405.

 

Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis 2003;14:425-431.

 

Sever P.  ALLHAT: definitive answers or continuing uncertainty?  JRAAS 2003;1:3-5.

 

Sever PS, Dahlöf   B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.   Lancet 2003:361;1149-1158.

 

Felmeden DC, Spencer CG, Blann AD, Beevers DG, Lip GY. Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Intern Med 2003;253:81-91.

 

Nadar S, Lim HS, Beevers DG, Lip GY. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. J Hum Hypertens 2002;16:815-817.

 

Scott R.  Answering the unanswered questions: ongoing trials of statins and antihypertensives in type 2 diabetes. Acta Diabetol 2002;39 Suppl 2:S46-51.*

 

Blood Pressure Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet  2003;362:1527-1535.

 

2002

Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY; ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002;40:61-66.


2001

Francis D, Lane R, Mayet J, Foale RA, Thom S, Peters NS; Anglo-Scandinavian Cardiac Outcomes Trial. Microvolt T wave alternans in patients with hypertension and left ventricular hypertrophy. J Hum Hypertens 2001;15 Suppl 1:S95-S96.

 

Jönsson B, Buxton M, Kahan T, Poulter NR, Svarvar P; Anglo-Scandinavian Cardiac Outcomes Trial, Health Economic Working Group. The effects of cardiac events on quality of life and indirect costs. J Hum Hypertens 2001;15 Suppl 1;S91-S93.

 

Poulter NR, Caulfield M, Feder G; Anglo-Scandinavian Cardiac Outcomes Trial. Ethnic variations in response to a statin (EVIREST). J Hum Hypertens 2001;15 Suppl 1:S87-S89.

O'Neill H,  O'Brien E, Stanton A, Hedditch K; Anglo-Scandinavian Cardiac Outcomes Trial. The suitability of an automated blood pressure measuring device--the Omron HEM-705CP--in a large multicentre study: the ASCOT study.   J Hum Hypertens 2001;15 Suppl 1:S83-S85. 


Thom S, Whitehouse A, Sever P, Poulter N; Anglo-Scandinavian Cardiac Outcomes Trial. Non-specific effects of inclusion in a clinical trial: information from ASCOT. J Hum Hypertens  2001;Suppl 1:S81-82.

 

O'Hare JP; Anglo-Scandinavian Cardiac Outcomes Trial. Microalbuminuria in type 2 diabetic hypertensive patients in ASCOT. J Hum Hypertens 2001;15 Suppl 1:S79-S80.

 

O'Brien E, Gribbin C, Stanton A, Atkins N, Lyons S; Anglo-Scandinavian Cardiac Outcomes Trial. Left ventricular hypertrophy and silent ischaemia: a pilot study to examine the relationship in hypertensive patients. J Hum Hypertens 2001;15 Suppl 1:S75-S77.

 

Williams B, O'Rourke M; Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens 2001;15 Suppl 1:S69-S73.

 

Horne R, Clatworthy J, Polmear A, Weinman J; Anglo-Scandinavian Cardiac Outcomes Trial. Do hypertensive patients' beliefs about their illness and treatment influence medication adherence and quality of life? J Hum Hypertens 2001;15 Suppl 1: S65-S68.

 

Kirby PL, Caulfield MC, Collier DJ, Eldridge S, Griffiths CG, Hemingway H, Poulter NR, Feder GS; Anglo-Scandinavian Cardiac Outcomes Trial. Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group. J Hum Hypertens 2001;15 Suppl 1:S61-S64.

 

Collier DJ, Bernardi L, Angell-James JE, Caulfield MJ, Sleight P; Anglo-Scandinavian Cardiac Outcomes Trial. Baroreflex sensitivity and heart rate variability as predictors of cardiovascular outcome in hypertensive patients with multiple risk factors for coronary disease. J Hum Hypertens 2001;15 Suppl 1:S57-S60.

 

Jönsson B, Buxton M, Hertzman P, Kahan T, Poulter N; Anglo-Scandinavian Cardiac Outcomes Trial, Health Economics Working Group. Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Hum Hypertens 2001;15 Suppl 1:S53-S56.

 

O'Brien E, McInnes GT, Stanton A, Thom S, Caulfield M, Atkins N, Nichol FM; Anglo-Scandinavian Cardiac Outcomes Trial. Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients. J Hum Hypertens 2001;15 Suppl 1:S47-S51.

 

Oikarinen L, Viitasalo M, Toivonen L, Nieminen MS; Anglo-Scandinavian Cardiac Outcomes Trial.   Comparative effects of atenolol-based and amlodipine-based antihypertensive therapy on QT dispersion in hypertensive subjects. J Hum Hypertens 2001;15 Suppl 1:S43-S45.

 

Spencer CG, Beevers DG, Lip GY; Anglo-Scandinavian Cardiac Outcomes Trial.   Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of antihypertensive treatment. J Hum Hypertens 2001;15 Suppl 1:S39-S42.

 

Julkunen J; Anglo-Scandinavian Cardiac Outcomes Trial. Health-related quality of life and psychological factors in treatment of hypertension. J Hum Hypertens 2001;15 Suppl 1:S35-S38.

 

Wilson S, Collier D, Johnston A, Poulter N, Feder G, Robson J, Caulfield M; Anglo-Scandinavian Cardiac Outcomes Trial. Evaluation of cardiovascular risk equations using the ASCOT cohort. J Hum Hypertens 2001;15 Suppl 1:S31-S33.

 

Nieminen MS, Viikari J, Ahotupa M, Vasankari T, Kantola I, Strandberg T, Vanhanen H; Anglo-Scandinavian Cardiac Outcomes Trial. Effects of atorvastatin (and blood pressure lowering comparing amlodipide-based therapy with beta-blocker-based therapy) on serum variables of cholesterol synthesis and absorption, thrombogenicity and on low-density lipoprotein oxidation in vivo. J Hum Hypertens 2001;15 Suppl 1:S27-S29.

 

Chapman JN, Kirby P, Caulfield MC, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial.   Cardiovascular risk factors in a cohort of 30,000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).   J Hum Hypertens 2001;15 Suppl 1:S23-26.

 

Uusimaa P, Tokola H, Ruskoaho H, Vuolteenaho O, Risteli J, Ylitalo A, Peuhkurinen K; Anglo-Scandinavian Cardiac Outcomes Trial. Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics. J Hum Hypertens 2001;15 Suppl 1:S19-S22.

 

Stanton A, Fitzgerald D, Hughes A, Mayet J, O'Brien E, Poulter NR, Sever PS, Shields D, Thom S; Anglo-Scandinavian Cardiac Outcomes Trial.   An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease. J Hum Hypertens  2001;15 Suppl 1:S13-18.

 

Sever PS, Dahlöf   B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial. Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. J Hum Hypertens  2001;15 Suppl 1:S11-12.

 

Sever PS, Dahlöf   B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.   Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens  2001;6:1139-1147.

 

 




Go To Top ∆